Udemy, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Udemy, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $518.41M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $491.94M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $419.34M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $353.78M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $279.63M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $220.65M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $132.82M | Apr 13, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.81M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($85.29M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($107.29M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($153.88M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($80.03M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($77.62M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($69.70M) | Apr 13, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.16M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($89.33M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($121.90M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($151.19M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($77.91M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($73.38M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($68.03M) | Apr 13, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.51M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $125.44M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $120.34M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $104.56M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $66.11M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $50.64M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $34.38M | Apr 13, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.66M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $53.04M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($2.01M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($60.96M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($7.10M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $9.62M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($16.46M) | Apr 13, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.80M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $632.0K | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.56M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $5.34M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $5.18M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $3.33M | Apr 13, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $617.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $605.63M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $741.20M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $737.57M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $739.85M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $282.10M | Apr 13, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $407.24M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $408.23M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $384.30M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $398.26M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $350.15M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $268.68M | Apr 13, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $210.46M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $197.39M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $356.89M | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $339.31M | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $389.70M | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | ($260.69M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2019 | ($225.59M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | ($183.57M) | Apr 13, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.65M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $12.65M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $12.65M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $12.65M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $12.65M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 13, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($801.18M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($804.99M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($719.70M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($612.40M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($458.53M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($378.50M) | Apr 13, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $231.49M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $190.59M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $305.56M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $313.69M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $533.87M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $175.03M | Feb 27, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Apr 13, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Apr 13, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 145.05M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 147.48M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 157.17M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 145.01M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 139.16M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 35.63M | Apr 13, 2022 |